A message for CPG CEOs, founders, and private equity investors: Ask the uncomfortable questions now
The GLP-1 case set out here is one worked example of a broader question whether Canada analyzes pharmacare as current-period cost or as long-horizon fiscal investment
At the same time, pharma companies continue developing lower-volume therapiesmaking it essential for CDMOs to support both large-scale and niche projects
Although mild, the most common ones include heat discomfort, dehydration, low blood pressure, lightheadedness, and nausea
Boosting our bodys endogenous GLP-1 production offers a natural alternative or complement to pharmaceutical interventions
A single fresh receptor can produce near-maximum output at about 10% engagement, while a normal meal uses only 1% to 4% (receptor saturation). That snapshot does not describe what happens after continuous weekly exposure